Rufinamide: a new antiepileptic drug treatment for Lennox-Gastaut syndrome.

abstract：:Dystonia may be a sign or symptom, that is comprised of complex abnormal and dynamic movements of different etiologies. A specific cause is identified in approximately 28% of patients, which only occasionally results in specific treatment. In most cases, treatment is symptomatic and designed to relieve involuntary mov...

journal_title：Expert review of neurotherapeutics

authors： Bhidayasiri R,Tarsy D

更新日期：2006-06-01 00:00:00

abstract：:The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the years 2010-2012. The natalizumab section gives a progressive multifocal leukoencephalopathy update, focusing on clinically relevant aspects. Furthermore, it outlines problems around natalizum...

journal_title：Expert review of neurotherapeutics

authors： Deiß A,Brecht I,Haarmann A,Buttmann M

更新日期：2013-03-01 00:00:00

abstract：INTRODUCTION:The increasing development and availability of portable and wearable technologies is rapidly expanding the field of technology-based objective measures (TOMs) in neurological disorders, including Parkinson disease (PD). Substantial challenges remain in the recognition of disease phenomena relevant to patie...

journal_title：Expert review of neurotherapeutics

authors： Merola A,Sturchio A,Hacker S,Serna S,Vizcarra JA,Marsili L,Fasano A,Espay AJ

更新日期：2018-11-01 00:00:00

abstract：:Introduction: Paroxysmal dyskinesias and episodic ataxias are often caused by mutations in genes related to cell membrane and synaptic function. Despite the exponential increase in publications of genetically confirmed cases, management remains largely clinical based on non-systematic evidence. Areas covered: The auth...

journal_title：Expert review of neurotherapeutics

authors： De Gusmao CM,Silveira-Moriyama L

更新日期：2019-09-01 00:00:00

abstract：INTRODUCTION:Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system (CNS). The modern treatment era for MS witnessed a growing pool of drugs now available for use in clinical practice. These therapies work at different levels, however there is a lack of treatments acting on the neurode...

journal_title：Expert review of neurotherapeutics

authors： Ruggieri S,Tortorella C,Gasperini C

更新日期：2017-11-01 00:00:00

abstract：INTRODUCTION:Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleedin...

journal_title：Expert review of neurotherapeutics

authors： Arnao V,Riolo M,Tuttolomondo A,Pinto A,Fierro B,Aridon P

更新日期：2017-06-01 00:00:00

abstract：:Sumatriptan 85 mg with naproxen sodium 500 mg, a combination tablet for the acute treatment of migraine, is approved in the USA. It is likely that triptan/NSAID combination benefits are a class effect, although the majority of data are on sumatriptan and naproxen sodium. The combination tablet demonstrated superior ef...

journal_title：Expert review of neurotherapeutics

authors： Cleves C,Tepper SJ

更新日期：2008-09-01 00:00:00

abstract：:With increasing life expectancy, the early diagnosis and treatment of Alzheimer's disease has become critical in sustaining a healthy society. Noninvasive markers of disease progression starting from the earliest stages of pathologic involvement are required for determining the effectiveness of putative disease-modify...

journal_title：Expert review of neurotherapeutics

authors： Kantarci K

更新日期：2005-09-01 00:00:00

abstract：:Alzheimer's disease is an age-related dementia and its incidence is rising in developed countries as the population ages. Amyloid plaques and tau-rich neurofibrillary tangles are pathologic hallmarks of the disease. Treatment is symptomatic, consisting of compounds that block enzymatic acetylcholine degradation (acety...

journal_title：Expert review of neurotherapeutics

authors： Silverberg GD,Mayo M,Saul T,Carvalho J,McGuire D

更新日期：2004-01-01 00:00:00

abstract：:Attention-deficit/hyperactivity disorder (ADHD) is a highly heritable condition that affects a significant number of children and adults worldwide. During the past 30 years, the diagnosis and treatment of ADHD has relied on clinical assessment and empirical experience with stimulant medications. More recently, advance...

journal_title：Expert review of neurotherapeutics

authors： Staller JA,Faraone SV

更新日期：2007-04-01 00:00:00

abstract：:The proper management of acute pain has been identified as a primary indicator of quality assurance in US trauma centers. Nearly half of all trauma patients are injured while intoxicated and 75% of these patients have chronic alcohol problems. The management of pain caused by injuries in patients with alcohol problems...

journal_title：Expert review of neurotherapeutics

authors： Askay SW,Bombardier CH,Patterson DR

更新日期：2009-02-01 00:00:00

abstract：:There is great concern over cardiovascular disease in the schizophrenic population owing to the high incidence of cardiovascular mortality. Increased cardiovascular mortality is related to lifestyle choices (e.g., smoking and sedentary lifestyle) and a high prevalence of comorbid medical conditions, including dyslipid...

journal_title：Expert review of neurotherapeutics

authors： Michelsen JW,Meyer JM

更新日期：2007-07-01 00:00:00

abstract：:In different study populations, several studies have shown that modest C-reactive protein elevation, in the range of apparently healthy individuals, is a strong predictor of future vascular events. Willcox and colleagues summarize the epidemiological and clinical observations that have led to the enthusiastic suggesti...

journal_title：Expert review of neurotherapeutics

authors： Di Napoli M,Papa F

更新日期：2004-07-01 00:00:00

abstract：:Introduction: Alzheimer's disease (AD), a commonly encountered neurodegenerative disorder, causes cognitive decline and has a devastating effect on the quality of life. AD occurs mainly through abnormal amyloid β peptide (Aβ) and tau protein (tau) activity around/in neurons. Aβ-based therapeutic techniques have been s...

journal_title：Expert review of neurotherapeutics

authors： Kuo YC,Rajesh R

更新日期：2019-07-01 00:00:00

abstract：:The aim of this article is to provide an overview on neuromuscular blocking agents and a rational selection of the most appropriate agents, along with pharmacological and pharmacoeconomic considerations on neuromuscular blockers and their antagonists. Neuromuscular blocking agents are used during anesthesia to facilit...

journal_title：Expert review of neurotherapeutics

authors： Leykin Y,Pellis T,Vincenti E

更新日期：2006-12-01 00:00:00

abstract：:According to the corticoid receptor hypothesis of depression, hyperactivity of the hypothalamic-pituitary-adrenocortical (HPA) system is one of the major pathophysiological factors for the development of depression and opens a broad range of new antidepressant treatment options that are related to direct interventions...

journal_title：Expert review of neurotherapeutics

authors： Schüle C,Baghai TC,Eser D,Rupprecht R

更新日期：2009-07-01 00:00:00

abstract：:Seizures are often the presenting symptoms of a cerebral tumor and may precede its diagnosis by many years. The article under evaluation searched two large English registries for patients admitted for new-onset epilepsy. The risk of subsequently being diagnosed with a malignant brain tumor was found to be 26-fold high...

journal_title：Expert review of neurotherapeutics

authors： Schucht P,Duffau H

更新日期：2011-08-01 00:00:00

abstract：:Pharmacotherapy, psychotherapy and other nonpharmacological interventions are used in patients with major depressive disorder (MDD). However, 50% of the patients with MDD fail to achieve a response to first-line antidepressant treatment. In four of five acute monotherapy studies, once-daily extended-release quetiapine...

journal_title：Expert review of neurotherapeutics

authors： Weisler R,McIntyre RS

更新日期：2013-11-01 00:00:00

abstract：:Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding. ...

journal_title：Expert review of neurotherapeutics

authors： Kobelt G

更新日期：2013-12-01 00:00:00

abstract：:Central nervous system idiopathic inflammatory demyelinating disorders are a heterogenous group of diseases that share inflammation and demyelination as key features. Although the exact pathophysiology remains to be fully unveiled, these conditions are challenging to clinicians who seek specific therapeutic options fo...

journal_title：Expert review of neurotherapeutics

authors： Khoshnam M,Freedman MS

更新日期：2012-09-01 00:00:00

abstract：:Pseudotumor cerebri (PTC) is characterized by intracranial hypertension without ventriculomegaly, in the absence of a mass lesion or meningeal process. When there is no secondary cause, it is termed 'idiopathic intracranial hypertension'. Headache is the most common symptom of PTC, present in over 90% of patients. The...

journal_title：Expert review of neurotherapeutics

authors： Friedman DI

更新日期：2008-03-01 00:00:00

abstract：INTRODUCTION:Neurodegenerative processes occur from the beginning of multiple sclerosis, contribute to irreversible clinical disability and are only partially addressed by current disease-modifying therapies. Reliable quantification of neuro-axonal damage may contribute to improve the assessment of disease activity and...

journal_title：Expert review of neurotherapeutics

authors： Preziosa P,Rocca MA,Filippi M

更新日期：2020-08-01 00:00:00

abstract：:Non-pharmacological interventions have the potential to reduce cognitive decline and to improve psychosocial aspects in mild cognitive impairment and Alzheimer's dementia, and the absence of side effects makes them a favorable option also for preventive strategies. We provide an overview on recent studies involving co...

journal_title：Expert review of neurotherapeutics

authors： Herholz SC,Herholz RS,Herholz K

更新日期：2013-11-01 00:00:00

abstract：:Parkinson's disease is a chronic neurodegenerative disorder leading to progressive motor impairment for which there is no cure. Currently, the diagnosis is made by the presence of cardinal motor features and several associated non-motor symptoms. However, at this point, the underlying neuropathological changes are alr...

journal_title：Expert review of neurotherapeutics

authors： Akhtar RS,Stern MB

更新日期：2012-12-01 00:00:00

abstract：:In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

journal_title：Expert review of neurotherapeutics

authors： Buttmann M,Rieckmann P

更新日期：2007-03-01 00:00:00

abstract：INTRODUCTION:Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. Baclofen, dantrolene, diazepam and gabapentin have been used as first-line options to treat these conditions, with modest results. Medical use of marijuana smoking has bypassed traditional clinical trials...

journal_title：Expert review of neurotherapeutics

authors： Fragoso YD,Carra A,Macias MA

更新日期：2020-08-01 00:00:00

abstract：:Alzheimer's disease is the most common form of neurodegenerative dementia and poses considerable health challenges to both patients and their families. Rivastigmine is a powerful slow-reversible, noncompetitive carbamate cholinesterase inhibitor that is approved for the treatment of mild-to-moderate Alzheimer's diseas...

journal_title：Expert review of neurotherapeutics

authors： Desai AK,Grossberg GT

更新日期：2005-09-01 00:00:00

abstract：:In the 1990s, cladribine was developed as an adenosine deaminase-resistant nucleoside analog with selective lymphotoxic specificity in the hope that it might become useful in the treatment of some lymphoid neoplasms and autoimmune disorders. Several clinical trials demonstrated very significant effectiveness and safet...

journal_title：Expert review of neurotherapeutics

authors： Sipe JC

更新日期：2005-11-01 00:00:00

abstract：:Spasticity is a common complication of CNS injury and a cause of considerable discomfort and disability for the patient and difficulty for caregivers. It is estimated that over half a million people in the USA are affected by spasticity. In recent years, advances in the treatment of spasticity include the use of intra...

journal_title：Expert review of neurotherapeutics

authors： Sheean G

更新日期：2003-11-01 00:00:00

abstract：:Epilepsy is one of the most common neurologic disorders in childhood that often requires long term treatment with antiepileptic drugs. Both antiepileptic treatment and the comorbidities associated with epilepsy have a negative impact on bone health in growing children. Given the fact that vitamin D deficiency is a maj...

journal_title：Expert review of neurotherapeutics

authors： Cebeci AN,Ekici B

更新日期：2014-05-01 00:00:00